摘要
目前临床使用的肺癌分期是国际抗癌联盟(Union for International Cancer Control,UICC)于2009年1月颁布的第七版TNM分期。近年来,随着肺癌诊断技术的提高以及个体化治疗、分子靶向治疗等精准治疗模式的改变,肺癌的生存率及预后也有了明显的提高,旧的分期标准已难以适应当前的快速发展的临床需求。因此国际肺癌研究学会(International Association for the Study of Lung Cancer,IASLC)2015年对肺癌分期系统进行了更新,其修订稿发表于《Journal of Thoracic Oncology》,新版分期计划于2017年1月正式颁布实施。新分期标准采纳了来自16个国家的35个数据库,包含了自1999年-2010年间新发病的94,708例肺癌病例。新版分期的优势在于能够更好的显示患者的预后,对临床具有更高的指导价值。
The currently adopted staging system for lung cancer is the seventh edition of the TNM staging edited by Union for International Cancer Control（UICC） in January, 2009. In recent years, with the advances of techniques in lung cancer diagnosis and the treatment trends towards precision treatment modalities such as individualized therapy and molecular targeted therapy, the survival and prognosis of lung cancer has been significantly improved. The old staging standard is difficult to satisfy the currentrapidly developing clinical needs. Therefore, the International Lung Cancer Research Society（International Association for the Study of Lung Cancer, IASLC） updated the stage of lung cancer in 2015, and the forthcoming eighth edition of the TNM Classification for Lung Cancer, which will be formally adopted in Jan. 2017, has been published in Journal of Thoracic Oncology. The new staging system has adopted 35 databases from 16 countries, including 94,708 cases treated between 1999 and 2010. The advantages of the new staging lies in its higher prognosis prediction and clinical guidance value.
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2016年第6期337-342,共6页
Chinese Journal of Lung Cancer
关键词
肺肿瘤
TNM分期
诊断
治疗
Lung neoplasms
TNM Stage
Diagnosis
Treatment
作者简介
通讯作者：赵珩，E-mail：h_zhao28@163．com
